Logo

CTOR

Citius Oncology, Inc.

CTOR

Citius Oncology, Inc. • NASDAQ
$1.37 ▲ 8.73% (+0.11)
Market Cap $114.41 M
52w High $6.19
52w Low $0.55
Dividend Yield 0%
P/E -3.51
Volume 75.94K
Outstanding Shares 83.51M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.945M ▼ $-5.37M ▲ 0% $-0.075 ▲ $-4.945M ▲
Q2-2025 $0 $7.471M ▲ $-7.736M ▼ 0% $-0.11 ▼ $-7.471M ▼
Q1-2025 $0 $6.395M ▼ $-6.659M ▲ 0% $-0.093 ▲ $-6.395M ▲
Q4-2024 $0 $6.669M ▲ $-6.813M ▼ 0% $-0.098 ▼ $-6.669M ▼
Q3-2024 $0 $4.629M $-4.773M 0% $-0.071 $252.462K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $112 $91.709M ▲ $59.311M ▲ $32.398M ▼
Q2-2025 $112 $91.439M ▲ $55.797M ▲ $35.643M ▼
Q1-2025 $112 $90.481M ▲ $49.192M ▲ $41.29M ▼
Q4-2024 $112 ▼ $84.369M ▲ $38.229M ▲ $46.14M ▲
Q3-2024 $261 $49.194M $3.081M $46.113M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-5.369K ▲ $0 $0 $0 $0 $0
Q2-2025 $-7.735K ▲ $0 $0 $0 $0 $0
Q1-2025 $-6.659M ▼ $0 ▼ $0 ▲ $0 ▼ $0 $0 ▼
Q4-2024 $0 ▼ $126.353 ▲ $-5K ▲ $4.873K ▼ $0 $126.353 ▲
Q3-2024 $252.462K $-364.055K $-22.548K $353.654K $0 $-364.06K

Five-Year Company Overview

Income Statement

Income Statement Citius Oncology is still in the pre‑commercial phase financially. The company has reported essentially no product revenue in recent years and is operating at a modest but persistent loss, mainly from research, development, and early commercialization setup. Losses have inched higher as the company prepares for launch, which is normal for a biotech just transitioning from development to commercialization. Profitability will depend almost entirely on how quickly and broadly its lead product, LYMPHIR, gains traction once fully launched.

Balance Sheet

Balance Sheet The balance sheet is small but relatively simple: a modest asset base, some shareholder equity, and effectively no recorded debt. This indicates the company has been funded mainly by equity rather than borrowing, which limits interest obligations but also means it may need further equity or partnership funding. The absence of a clear cash line in the summary data is a limitation, but management has already signaled that more capital will likely be required to support the commercial rollout and further clinical work.

Cash Flow

Cash Flow Reported cash flow data here are limited, but the overall picture is typical of an early-stage biotech: cash is being used rather than generated. Operating cash outflows are likely driven by R&D, regulatory work, and building commercial infrastructure. With no meaningful revenue yet, the company’s future cash position will depend on timely access to financing and on how efficiently it spends during the LYMPHIR launch period. Investors should assume ongoing cash burn until sales become established.

Competitive Edge

Competitive Edge Citius Oncology’s competitive position is built around a single, differentiated oncology product, LYMPHIR, for a rare form of T‑cell lymphoma. The drug has a distinctive targeted mechanism, regulatory approvals, orphan drug status, and potential for long biologic exclusivity in the U.S., all of which help protect its position. It operates in a niche market with significant unmet need and limited direct alternatives, which supports pricing power and adoption potential. Partnerships for commercialization and data‑driven marketing add further support, but the company’s narrow product focus also concentrates its risk in one main asset.

Innovation and R&D

Innovation and R&D Innovation is the core of Citius Oncology’s story. LYMPHIR is a targeted immunotherapy using a fusion of a receptor‑binding domain with a toxin to selectively kill cancer cells, a design that differentiates it from more traditional treatments. The company is exploring additional uses for LYMPHIR beyond its initial indication, including other lymphomas and combinations with checkpoint inhibitors and CAR‑T therapies. These efforts, along with ongoing clinical collaborations and a protected intellectual property position, give Citius room to expand its science into a broader franchise if trials are successful. However, development outcomes remain uncertain by nature, and delays or negative data would be meaningful setbacks.

Summary

Citius Oncology is an early‑stage commercial biotech moving from a development‑only model to a product‑driven model centered on LYMPHIR. Financially, it is still loss‑making with a small balance sheet and no real revenue base, relying on external capital to fund operations. Strategically, its strengths lie in a novel, approved oncology therapy, strong regulatory and IP protections, and a focused niche market with high unmet need, supported by experienced commercial partners and advanced analytics. Key uncertainties revolve around execution of the U.S. launch, pace of physician uptake, success of label expansions, and securing sufficient funding at acceptable terms. The company’s future trajectory will largely be determined by how effectively it converts this single, innovative asset into a durable, diversified oncology business.

NEWS

November 25, 2025 · 8:00 AM UTC

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Read more

November 21, 2025 · 8:37 AM UTC

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Read more

October 20, 2025 · 8:37 AM UTC

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

Read more

October 17, 2025 · 5:00 PM UTC

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Read more

October 16, 2025 · 8:47 AM UTC

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Read more